Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions

Journal of Interferon and Cytokine Research

Volumn 34, Issue 1, 2014, Pages 52-59

  Qu, Jing ^a   Hou, Zhaohua ^a   Han, Qiuju ^a   Jiang, Wen ^a   Zhang, Cai ^a   Tian, Zhigang ^a   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; POLYCYTIDYLIC ACID; ANTINEOPLASTIC AGENT; POLYINOSINIC POLYCYTIDYLIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CYTOLYSIS; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SUPERNATANT; ADENOCARCINOMA; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; STOMACH NEOPLASMS; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KILLER CELLS, NATURAL; POLY I-C; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84892151084     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0118     Document Type: Article

References (36)

1. Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W, 3rd. 2004. The antitumor effects of interferon-Alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res 116(1):129-136
2. Besch R, Poeck H, Hohenauer T, Senft D, Hacker G, Berking C, Hornung V, Endres S, Ruzicka T, Rothenfusser S, Hartmann G. 2009. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119(8):2399-2411
3. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG, Castle VP, Opipari AW, Jr. 2001. NF-kappa B activation mediates doxorubicin-induced cell death in N-Type neuroblastoma cells. J Biol Chem 276(52):48921-48929
4. Biron CA. 2001. Interferons alpha and beta as immune regulators -A new look. Immunity 14(6):661-664
5. Campbell KJ, Rocha S, Perkins ND. 2004. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 13(6):853-865
6. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. 2003. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237-249
7. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. 2001. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98(7):2183-2192
8. Chen X, Kandasamy K, Srivastava RK. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63(5):1059-1066
9. Cheng YS, Xu F. 2011. Anticancer function of polyinosinicpolycytidylic acid. Cancer Biol Ther 10(12):1219-1223
10. Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo B, Dempsey PW, Cheng G. 2010. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 70(7):2595-2603
11. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G. 2009. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J Immunol 182(7):4471-4478
12. Droller MJ, Gomolka D. 1982. Inhibition of tumor growth in association with modification of in vivo immune response by indomethacin and polyinosinic:polycytidylic acid. Cancer Res 42(12):5038-5045
13. Farag SS, Caligiuri MA. 2006. Human natural killer cell development and biology. Blood Rev 20(3):123-137
14. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, Balderas-Pena LM, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A. 2009. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186
15. Han Q, Zhang C, Zhang J, Tian Z. 2011. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 54(4):1179-1189
16. Ishibashi O, Ali MM, Luo SS, Ohba T, Katabuchi H, Takeshita T, Takizawa T. 2011. Short RNA duplexes elicit RIG-I-mediated apoptosis in a cell type-And length-dependent manner. Sci Signal 4(198):ra74
17. Lanier LL. 2008. Up on the tightrope: Natural killer cell activation and inhibition. Nat Immunol 9(5):495-502
18. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. 2001. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4):461-470
19. Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE, 3rd. 2003. The antitumor effects of IFN-Alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112(2):170-180
20. Levine AS, Levy HB. 1978. Phase I-II trials of poly IC stabilized with poly-L-lysine. Cancer Treat Rep 62(11):1907-1912
21. Lunemann A, Lunemann JD, Munz C. 2009. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med 15(9-10):352-358
22. Meyer HJ, Wilke H. 2011. Treatment strategies in gastric cancer. Dtsch Arztebl Int 108(41):698-705; quiz 706
23. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. 2001. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 276(27):24965-24970
24. Navabi H, Jasani B, Reece A, Clayton A, Tabi Z, Donninger C, Mason M, Adams M. 2009. A clinical grade poly I:C-Analogue (Ampligen) promotes optimal DC maturation and Th1-Type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1):107-115
25. Oka M, Mitsunaga H, Hazama S, Yoshino S, Suzuki T. 1993. Natural killer activity and serum immunosuppressive acidic protein levels in esophageal and gastric cancers. Surg Today 23(8):669-674
26. Oldham RK, Dillman RO. 2009. Principles of Cancer Biotherapy. London, UK: Springer, p. 1-17
27. Peng S, Geng J, Sun R, Tian Z, Wei H. 2009. Polyinosinicpolycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 100(3):529-536
28. Pfeffer LM. 2011. The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res 31(7):553-559
29. Rosenne E, Shakhar G, Melamed R, Schwartz Y, Erdreich-Epstein A, Ben-Eliyahu S. 2007. Inducing a mode of NKresistance to suppression by stress and surgery: A potential approach based on low dose of poly I-C to reduce postoperative cancer metastasis. Brain Behav Immun 21(4): 395-408
30. Saito H, Osaki T, Ikeguchi M. 2012. Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer. Gastric Cancer 15(1):27-33
31. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. 2006. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176(8):4894-4901
32. Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P 2007. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13(15 Pt 1):4565-4574
33. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L. 2008. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nat Immunol 9(5):486-494
34. Tompkins MB. 2007. Gastric Cancer Reserch Trends. New York: Nova Science Publishers, Inc
35. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. 2008. Functions of natural killer cells. Nat Immunol 9(5):503-510
36. Yoneda K, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Fuke H, Yamamoto N, Masuya M, Horie R, Uchida K, Takei Y. 2008. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: Differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol 33(5):929-936